Opinion

Video

Integrating HER2-Directed Therapies Into Standard Care for NSCLC

Key Takeaways

  • HER2-directed therapies offer clinical, operational, and economic benefits in NSCLC management within managed care settings.
  • NSCLC patients with HER2 mutations are the primary beneficiaries of HER2-directed therapies, necessitating precise identification.
SHOW MORE

Panelists discuss how incorporating HER2-directed therapies into NSCLC management strategies within managed care settings impacts clinical outcomes, operational processes, and economic considerations, while emphasizing the importance of identifying and selecting patient populations most likely to benefit from these targeted treatments.

Video content above is prompted by the following:

  • Examine the clinical, operational, and economic implications of incorporating HER2-directed therapies into NSCLC management strategies within managed care settings.
  • Which NSCLC patient populations are most likely to benefit from HER2-directed therapies and how should clinicians approach patient selection? 
Related Videos
Screenshot of an interview with Ruben Mesa, MD
Justin Oldham, MD, MS, an expert on IPF
Ruben Mesa, MD
Amit Garg, MD, Northwell Health
4 KOLs are featured in this series
4 KOLs are featured in this series
Surbhi Sidana, MD, MBBS
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo